Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria

NCT01635127 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT01635127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01635127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2012
Completion date
May 31, 2017
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic urticaria